{
  "docId": "019de074-7472-72bc-8651-e49cc0d0319c",
  "docSlug": "c2a880ad0c526527fe8aa49c40270224",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 28,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7472-72bc-8651-e49cc0d0319c/14",
  "deckHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c",
  "deckJsonHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c.json",
  "deckAnchorHref": "/decks/019de074-7472-72bc-8651-e49cc0d0319c#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.7,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "chart",
      "text": "AB-729 Decreased Exhausted T-Cells",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d0860d1-145a-4026-9fd7-5e3906de34a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.7,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "AB-729 Increased HBV-Specific T-Cell Activation",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b1a1ac8-f41c-4536-b638-1a96b10a1e2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.72,
        "y": 0.5
      },
      "kind": "list",
      "text": "Upregulation of HBV-specific T-cell activation markers observed in all 7 patients assessed to date. Two profiles of HBV-specific T cell IFN-y responses observed. Elevation between Wk 16-28 which coincides with nadir of HBsAg reduction. Elevation after AB-729 dosing completed, between Wk 48-60",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96e7499a-2da0-41e3-9262-4eb4a238302c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.56,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Data presented at EASL 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1182ae2d-b42e-46fd-9401-f85a6b6949ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "AB-729-001: Treatment with AB-729 Reactivates HBV Specific Immunity in Some Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "886ea60d-d31d-4c53-a9ad-1bc454c14c5f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 8,
      "beatId": "8e825e5a-e303-4698-98f8-f2a022a4a5c6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline, including AB-729, AB-101, and AB-161, as a potential solution (p8-28).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 14,
      "from": 10,
      "beatId": "5dda647e-e3c1-4360-9757-fc347cc61491",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents data and results from clinical trials, including AB-729-001 (p10-14).",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}